Malignant News and Research

RSS

UVA researchers develop a new experimental approach to target glioblastoma

University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer.

22 Jul 2026

City of Hope launches trial to map how tumors change during immunotherapy resistance

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system's ability to fight disease.

21 Jul 2026

New BRAF protein conformation opens avenues for cancer treatment

Several types of cancer are triggered by mutations in a protein called BRAF. Researchers at the Paul Scherrer Institute PSI have resolved a previously unknown conformation adopted by this protein during cell proliferation.

21 Jul 2026

AI-guided technique improves targeted therapy delivery for brain tumors

Researchers presented a groundbreaking artificial intelligence (AI)-guided technique today at the Society of NeuroInterventional Surgery's (SNIS) 23rd Annual Meeting that may improve the accuracy of delivering experimental therapies directly to malignant brain tumors.

20 Jul 2026

KAIST study opens a new avenue for treating intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

19 Jul 2026

Blood-based gene tests show promise for pancreatic cancer screening

Researchers at Kanazawa University report the blood-based gene expression tests may enable early pancreatic cancer screening and improve long-term survival.

16 Jul 2026

Bifidobacterium-based oral vaccine enhances anti-tumor immunity in clinical study

A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.

14 Jul 2026

Advanced synthetic grafting material fights bone cancer and prevents infection

Primary bone tumors, such as osteosarcoma, have seen stagnant survival rates over the past four decades. Surgical removal of the tumor is critical, but local recurrence may occur when tumours are close to vital structures, often resulting in amputation.

9 Jul 2026

Case study shows how accurate diagnosis can guide personalized treatment for renal oncocytoma

A new case report was published in Volume 17 of Oncotarget on July 2, 2026, titled "Renal oncocytoma: Α case report and literature review."

6 Jul 2026

New synthetic grafting material kills bone cancer and regenerates bone

3 Jul 2026

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Study potential new therapeutic strategy for patients with ATRX-mutant gliomas

A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common genetic alterations in glioma rewires the cancer cell genome to fuel tumor progression, suggesting a potential new therapeutic strategy for patients with ATRX-mutant gliomas.

1 Jul 2026

Artificial intelligence improves diagnostic accuracy in clinical breast pathology

Artificial intelligence (AI) is increasingly reshaping diagnostic pathology, with breast pathology representing one of the most advanced and clinically impactful areas of adoption.

26 Jun 2026

Faster biological aging may explain rising early-onset cancers

The link between biological aging and early-onset cancer risk offers crucial insights into generational health trends and potential preventive measures.

24 Jun 2026

Scientists uncover new molecular mechanism driving gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations driving approximately 75% to 80% of cases.

23 Jun 2026

Brazilian researchers identify cell molecule that drives cancer progression

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.

18 Jun 2026

Dr. Dan Landau receives Lotus Award for ovarian cancer research

Dr. Dan Landau, the Bibliowicz Family Professor of Medicine, and a member of the Sandra and Edward Meyer Cancer Center and the Englander Institute for Precision Medicine at Weill Cornell Medicine, has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

15 Jun 2026

New genetic driver found for rare small intestinal cancers

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide, and renew themselves.

12 Jun 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

Brain injury survivors face higher risk of brain cancer death

Daniel Daneshvar, MD, PhD, director of the HealthSpan Lab and Chief of the Department of Physical Medicine and Rehabilitation at Mass General Brigham, and Charlotte Luster, of the HealthSpan Lab, are the senior and lead authors of a paper published in Neuroepidemiology, "Brain Cancer Mortality following Traumatic Brain Injury (TBI): A TBI Model Systems Study."

10 Jun 2026